Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 4/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14567326 | 0.80 | P2RX7 (0.38) | P2RX7BRD4 | |
| SCHEMBL5365854 | 0.78 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL8232195 | 0.78 | P2RX7 (0.40) | P2RX7BRD4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL6999553 | 0.78 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL5081569 | 0.78 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL288353 | 0.78 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL8422247 | 0.76 | MEN1 (0.39) | PRKCD | |
| SCHEMBL25251069 | 0.76 | P2RX7 (0.39) | P2RX7BRD4 | |
| Hydrochloric Acid SCHEMBL28572830 | 0.76 | P2RX7 (0.39) | P2RX7 | |
| Lithium Ion SCHEMBL30619228 | 0.74 | P2RX7 (0.38) | P2RX7BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377872-B2 | Non-structural protein-3 (NS-3) protease inhibitors; viricides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, CTSC, PREP | P2RX7 1739/4885BRD4 2092/4885CHRNB2 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.